Surgery better for most men with localised prostate cancer

February 27, 2014
Surgery better for most men with localised prostate cancer
Credit: Shutterstock

Surgery offers better survival rates for most men with localised prostate cancer than radiotherapy, according to one of the largest studies of its type.

The study, led by an Oxford University researcher, found that surgery as the first-line treatment offered greatest benefits for younger men in good general health.

The international research team from the UK, Sweden and the Netherlands compared data on what happened to more than 34,000 Swedish men over a 15-year period after they had been treated for prostate cancer.

It is hoped the findings, published online today in the British Medical Journal, could help inform treatment choice.

Around 350,000 men are diagnosed with prostate cancer in Europe each year and the lifetime risk of being diagnosed is one in six. In the UK alone, more than 110 men are diagnosed every day.

Surgical treatment of prostate cancer involves a procedure to remove the prostate gland, which can now be performed using robotic keyhole surgery. Radiotherapy gives a high dose of radiation to the .

Lead author Prasanna Sooriakumaran, from Oxford University's Nuffield Department of Surgical Sciences, said the study offered the best evidence to-date to compare the long-term outcomes of surgery and radiotherapy for prostate cancer.

But he was clear that the benefits of surgery related only to certain groups of patients with localised prostate cancer, where the disease had not spread to other parts of the body.

Mr Sooriakumaran, who is also a consultant surgeon at Oxford's Churchill Hospital, said: 'The study found that patients in what we would class as an intermediate or high-risk group who had surgery as their primary treatment had an increased survival rate.

'Benefits for surgery were also seen in low-risk prostate cancer patients but these men tended to do well whatever treatment they received.

'Further, the greatest benefits for surgery over radiotherapy were seen in younger men and those in better general health as these men were less likely to succumb to death from other causes and thus their prostate cancer became a life-threatening issue for them.'

The decision on whether to have surgery or radiotherapy is one for the patient and their consultant. At present, without clear evidence to compare what happens to patients in the long term, it can come down to personal choice based on the side effects of the treatments.

'We hope this study will play an important part in informing the decision-making process of the individual patient and his doctor regarding what treatment is best for him,' said Mr Sooriakumaran.

But he added: 'It is important that the results of this study are placed in the context of that overall discussion as to the most appropriate treatment for any given individual sufferer. We only looked at length of life and that in itself is only one consideration in choosing a treatment option.

'The side effects of different treatments will affect quality of life in different ways and some patients will value certain quality of life advantages for one treatment option as being more important than length of life.'

In this study virtually all men with prostate cancer diagnosed in Sweden from 1998 onwards were followed for up to 15 years using information from national databases. The researchers found that all the statistical models they used with the data demonstrated that men who had had surgery had better survival rates than those that had undergone radiotherapy.

Peter Wiklund, the study's senior author from Karolinska Institutet, said: 'The Swedish dataset we employed in this study is the world's most comprehensive and accurate data in survival outcomes for men with prostate cancer.'

While noting that there may be differences between Sweden and other parts of the world, including the the USA and UK, he added: 'Nevertheless, the finding that appears best in survival terms for most men with localised is highly compelling.'

Explore further: Surgery is superior to radiotherapy in men with localized PCa, Swedish study says

Related Stories

Surgery is superior to radiotherapy in men with localized PCa, Swedish study says

March 15, 2013
Surgery offers better survival benefit for men with localised prostate cancer, according to a large observational study, conducted by a group of researchers in Sweden and the Netherlands.

More intensive radiotherapy is better than less for localized prostate cancer

February 25, 2014
A radiotherapy regime involving higher doses of radiation is a better option than having lower doses for men with localised prostate cancer, the 10-year results of the largest trial of its kind have shown.

Radiotherapy plus hormone therapy cuts prostate cancer death in half, shows long-term study

January 30, 2014
Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin.

Scientists overcome barrier to prostate cancer research

October 24, 2013
Monash scientists have overcome one of the major barriers to the study and treatment of localised -or organ confined- prostate cancer.

Scientists finally discover which prostate cancers are life-threatening

November 19, 2013
Cancer Research UK scientists have discovered that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.

Radiotherapy after surgery has lasting benefits for prostate cancer patients

October 18, 2012
New research confirms that giving radiotherapy immediately after surgery to remove the prostate has long-term benefits for preventing the biochemical progression of the disease. After 10 years, 61 percent of men who received ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.